Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
Novartis Pharmaceuticals
Simon J Bowman; Robert Fox; Thomas Dörner; Xavier Mariette; Athena Papas; Thomas Grader-Beck; Benjamin A Fisher; Filipe Barcelos; Salvatore De Vita; Hendrik Schulze-Koops; Robert J Moots; Guido Junge; Janice N Woznicki; Monika A Sopala; Wen-Lin Luo; Wolfgang Hueber